Introduction
Global cervical cancer treatment market size is poised to reach around USD 11.2 bn by 2026, with registered 6.5% of CAGR during forecast period 2019 to 2026.
The industry is primarily driven by supportive government initiatives along with increasing better healthcare equipment, device, medicines and cervical cancer treatment.
Market Dynamics
Growing geriatric population and need for better treatment are among the main growth-driving factors. Increasing occurrence of numerous chronic diseases and growing numeral of hospitals and clinics in developing nations are also expected to expand the development of this market during the coming years.
Augmented illness occurrence, proactive government initiatives, and arrival of targeted therapies are the main factors contributing to the cervical cancer treatment market expansion. Cervical cancer has a high mortality rate that can be reduced by prevention and early diagnosis.
Market Insights
Absence of mindfulness about the conclusion and treatment techniques, staggering expense of treatment, and unfriendly impacts related with malignant growth treatment may upset the market development. In addition, absence of focused medications with enhanced clinical profile at decreased expenses and advantageous organization plan is likewise liable to block showcase development. Be that as it may, rising R and D consumption in oncologic ailments offer a promising future for the worldwide cervical malignant growth treatment market within recent years.
Hospital pharmacies caught the biggest offer of the worldwide market in 2018. Hospital pharmacies preserve the stock of device, medicine and equipment related to cervical cancer for in-patients, as well as out-patients. This segment will be driven further by developing customer mindfulness and expanded interests in human services framework in emerged and developing nations.
Market Segmentation
Market By Type
- Squamous Cell Carcinoma (SCC)
- Adenocarcinoma
- Adenosquamous Carcinoma
Market By Product
- Prevention
- Gardasil/Gardasil9
- Cervarix
- Treatment
- Avastin
- Keytruda
- Generics
- Others
Market By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market By Geography
- North America
- Europe
- UK
- Germany
- France
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Latin America
- Brazil
- Chile
- Rest of Latin America
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- Rest of MEA
Regional Insights
Europe drove the general market as far as revenue share in 2018. Continually enhancing social insurance foundation in the area is in charge of the market development. In addition, developing populace is adding to the market extension. The Asia Pacific district, then again, is probably going to witness the quickest CAGR over the forthcoming years.
Developing medicinal services use, and mindfulness about cancer are some of the key points driving the Asia Pacific market. Also, increasing need for better healthcare devices and treatment is driving the need for the market during the coming years.
Market Participants
Market companies are concentrating on implementing new strategies, for instance, regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share. The major players associated with the cervical cancer treatment market are Merck & Co, F. Hoffmann-LA Roche AG, Pfizer, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., AstraZeneca PLC, Biocon Ltd., Bristol-Myers Squibb, Eli Lilly & Co., and Allergan PLC. These players, broad R&D by significant organizations over the globe to launch cervical cancer treatment innovation with maximum safety and accuracy is relied upon to add to the market extension. Market companies are concentrating on implementing new strategies, for instance, regional expansion, partnerships, mergers and acquisitions, new product launches, and distribution agreements to surge their revenue share.
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Cervical Cancer Treatment
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Cervical Cancer Treatment Market By Type
1.2.2.1. Global Cervical Cancer Treatment Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Cervical Cancer Treatment Market Revenue Share By Type in 2017
1.2.2.3. Squamous Cell Carcinoma (SCC)
1.2.2.4. Adenocarcinoma
1.2.2.5. Adenosquamous Carcinoma
1.2.2.6. Others
1.2.3. Cervical Cancer Treatment Market By Product
1.2.3.1. Global Cervical Cancer Treatment Market Revenue and Growth Rate Comparison By Product (2015-2026)
1.2.3.2. Prevention
1.2.3.3. Treatment
1.2.3.4. Others
1.2.4. Cervical Cancer Treatment Market By Distribution Channel
1.2.4.1. Global Cervical Cancer Treatment Market Revenue and Growth Rate Comparison By Distribution Channel (2015-2026)
1.2.4.2. Hospital Pharmacies
1.2.4.3. Retail Pharmacies
1.2.4.4. Online Pharmacies
1.2.4.5. Others
1.2.5. Cervical Cancer Treatment Market by Geography
1.2.5.1. Global Cervical Cancer Treatment Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.5.2. North America Cervical Cancer Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.3. Europe Cervical Cancer Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.4. Asia-Pacific Cervical Cancer Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.5. Latin America Cervical Cancer Treatment Market Revenue and Growth Rate (2015-2026)
1.2.5.6. Middle East and Africa (MEA) Cervical Cancer Treatment Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Cervical Cancer Treatment Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Cervical Cancer Treatment Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Cervical Cancer Treatment Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Cervical Cancer Treatment Major Manufacturers in 2017
CHAPTER 4. CERVICAL CANCER TREATMENT MARKET BY TYPE
4.1. Global Cervical Cancer Treatment Revenue By Type
4.2. Squamous Cell Carcinoma (SCC)
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Adenocarcinoma
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Adenosquamous Carcinoma
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Other
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. CERVICAL CANCER TREATMENT MARKET BY PRODUCT
5.1. Global Cervical Cancer Treatment Revenue By Product
5.2. Prevention
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Treatment
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. CERVICAL CANCER TREATMENT MARKET BY DISTRIBUTION CHANNEL
6.1. Global Cervical Cancer Treatment Revenue By Distribution Channel
6.2. Hospital Pharmacies
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Retail Pharmacies
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Online Pharmacies
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. NORTH AMERICA CERVICAL CANCER TREATMENT MARKET BY COUNTRY
7.1. North America Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. North America Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
7.3. U.S.
7.3.1. U.S. Cervical Cancer Treatment Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.4. Canada
7.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
7.5. Mexico
7.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
7.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 8. EUROPE CERVICAL CANCER TREATMENT MARKET BY COUNTRY
8.1. Europe Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Europe Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. UK
8.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.4. Germany
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.5. France
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.6. Spain
8.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
8.7. Rest of Europe
8.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
8.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 9. ASIA-PACIFIC CERVICAL CANCER TREATMENT MARKET BY COUNTRY
9.1. Asia-Pacific Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Asia-Pacific Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. China
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.4. Japan
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.5. India
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.6. Australia
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.6.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.7. South Korea
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.7.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
9.8. Rest of Asia-Pacific
9.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.8.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
9.8.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 10. LATIN AMERICA CERVICAL CANCER TREATMENT MARKET BY COUNTRY
10.1. Latin America Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Latin America Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. Brazil
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.4. Argentina
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
10.5. Rest of Latin America
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
10.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 11. MIDDLE EAST CERVICAL CANCER TREATMENT MARKET BY COUNTRY
11.1. Middle East Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Middle East Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Saudi Arabia
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.4. UAE
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
11.5. Rest of Middle East
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
11.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 12. AFRICA CERVICAL CANCER TREATMENT MARKET BY COUNTRY
12.1. Africa Cervical Cancer Treatment Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Africa Cervical Cancer Treatment Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. South Africa
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.3.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.4. Egypt
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.4.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
12.5. Rest of Africa
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By Product, 2015 - 2026 ($Million)
12.5.3. Market Revenue and Forecast By Distribution Channel, 2015 - 2026 ($Million)
CHAPTER 13. COMPANY PROFILE
13.1. Merck & Co
13.1.1. Company Snapshot
13.1.2. Overview
13.1.3. Financial Overview
13.1.4. Type Portfolio
13.1.5. Key Developments
13.1.6. Strategies
13.2. F. Hoffmann-LA Roche AG
13.2.1. Company Snapshot
13.2.2. Overview
13.2.3. Financial Overview
13.2.4. Type Portfolio
13.2.5. Key Developments
13.2.6. Strategies
13.3. Pfizer, Inc.
13.3.1. Company Snapshot
13.3.2. Overview
13.3.3. Financial Overview
13.3.4. Type Portfolio
13.3.5. Key Developments
13.3.6. Strategies
13.4. GlaxoSmithKline PLC
13.4.1. Company Snapshot
13.4.2. Overview
13.4.3. Financial Overview
13.4.4. Type Portfolio
13.4.5. Key Developments
13.4.6. Strategies
13.5. AstraZeneca PLC
13.5.1. Company Snapshot
13.5.2. Overview
13.5.3. Financial Overview
13.5.4. Type Portfolio
13.5.5. Key Developments
13.5.6. Strategies
13.6. Biocon Ltd.
13.6.1. Company Snapshot
13.6.2. Overview
13.6.3. Financial Overview
13.6.4. Type Portfolio
13.6.5. Key Developments
13.6.6. Strategies
13.7. Bristol-Myers Squibb
13.7.1. Company Snapshot
13.7.2. Overview
13.7.3. Financial Overview
13.7.4. Type Portfolio
13.7.5. Key Developments
13.7.6. Strategies
13.8. Eli Lilly & Co
13.8.1. Company Snapshot
13.8.2. Overview
13.8.3. Financial Overview
13.8.4. Type Portfolio
13.8.5. Key Developments
13.8.6. Strategies
13.9. Allergan PLC
13.9.1. Company Snapshot
13.9.2. Overview
13.9.3. Financial Overview
13.9.4. Type Portfolio
13.9.5. Key Developments
13.9.6. Strategies
13.10. Others
13.10.1. Company Snapshot
13.10.2. Overview
13.10.3. Financial Overview
13.10.4. Type Portfolio
13.10.5. Key Developments
13.10.6. Strategies
CHAPTER 14. RESEARCH APPROACH
14.1. Research Methodology
14.1.1. Initial Data Search
14.1.2. Secondary Research
14.1.3. Primary Research
14.2. Assumptions and Scope
